←
Devin Effinger, PhD612 posts
Devin Effinger, PhD avatar

Devin Effinger, PhD

@devin_effinger

PhD neuroscientist building precision neurotechnology for psychedelic-assisted therapy. Founder @ Psio + NeuroRecovery | TEDx Speaker

◷ Joined December 2020▧ 137 Photos and videos
NPP-Digital Psychiatry and Neuroscience (DPN) avatar
⟳ Devin Effinger, PhD retweeted
NPP-Digital Psychiatry and Neuroscience (DPN)@dpn_journal·13 Nov 2025

Researchers with lived experience of mental illness or SUDs bring vital expertise & insight to our field, yet remain underrepresented and face barriers to participation and leadership. This Perspective from @UmaRChatterjee, @SchumerMaya, @devin_effinger, @viscidula, @noelvest, Michael Cahill, @BStaglin, @EricJNestler calls for breaking these barriers and proposes actionable strategies to build more inclusive environments by reforming admissions, mentorship, and leadership pathways. nature.com/articles/s44277-0…

The Transmitter avatar
⟳ Devin Effinger, PhD retweeted
The Transmitter@_TheTransmitter·1 Oct 2025

Devin Effinger @devin_effinger and @MelissaHerman4 argue that, though many human psychedelic clinical trials are underway, preclinical studies remain our best bet to answer fundamental questions about the neurobiology of psychedelics. thetransmitter.org/psychedel…

Devin Effinger, PhD avatar
Devin Effinger, PhD@devin_effinger·29 Sep 2025

What an honor! Humbled and grateful. It was a beautiful disaster and a perfect metaphor for my recovery ending with a standing ovation. Thank you so much to the organizers and stay tuned for the link! @TEDxBoulder

Post attachment
Devin Effinger, PhD avatar
Devin Effinger, PhD@devin_effinger·23 Aug 2025

Takeaway: In mice, 8 weeks of low-dose LSD produced no evidence of heart damage. But human studies are still essential — especially in people with cardiovascular risk factors.

Devin Effinger, PhD avatar
Devin Effinger, PhD@devin_effinger·23 Aug 2025

Pharmacokinetic modeling gave us a potential explanation: 👉 Fenfluramine is still present in blood at 24h, leading to sustained and chronic 5-HT2B activation. 👉 Low doses of LSD and psilocin are both off the receptor within 8-10h.

Devin Effinger, PhD avatar
Devin Effinger, PhD@devin_effinger·23 Aug 2025

We tested this by giving mice low-dose LSD (microdoses) 5 days per week for 8 weeks and tracked heart structure and function with echocardiography. 🫀 Serotonin & fenfluramine (positive controls) led to ventricular or valvular remodeling. 🫀 LSD had no effects.

Devin Effinger, PhD avatar
Devin Effinger, PhD@devin_effinger·23 Aug 2025

🚨 New paper 🚨 For years, there has been concern that psychedelics might pose cardiovascular risks due to their agonist activity at the 5-HT2B receptor — the same target linked to drug-induced heart disease. pubs.acs.org/doi/full/10.102…

Maya Schumer, PhD! avatar
⟳ Devin Effinger, PhD retweeted
Maya Schumer, PhD!@SchumerMaya·13 Aug 2025

@ACNPorg brought @UmaRChatterjee @devin_effinger & me together last year: After finding each other on X-as we are all public/open about our lived experience -we met and discussed the ideas for this Study Group! Looking forward to doing this work together@ #ACNP2026🧠❤️💥‼️

THRILLED to share @ACNPorg news x2! 1) Our study group—“Centering Lived Experience in Psychiatric Neuroscience Research: Challenges, Opportunities, & Calls to Action” @EricJNestler @BStaglin @SchumerMaya @devin_effinger @viscidula @noelvest @MichaelECahill1=ACCEPTED! 🤩#ACNP2026

Post attachment
Devin Effinger, PhD avatar
Devin Effinger, PhD@devin_effinger·31 Jul 2025

It’s wild how much change is possible in this life. From relearning to talk post-TBI, to full blown heroin addiction, to a life beyond anything I could have imagined. Im very fortunate to not only be alive, but to have been selected to speak at 2025 TEDxBoulder!

Post attachment